Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.

AKYILDIZ M., Gunsar F. , Ersoz G. , KARASU Z. , ILTER T., BATUR Y., ...Daha Fazla

Digestive diseases and sciences, cilt.52, ss.3444-7, 2007 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 52 Konu: 12
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1007/s10620-006-9718-8
  • Dergi Adı: Digestive diseases and sciences
  • Sayfa Sayıları: ss.3444-7

Özet

We studied clinical and laboratory effects of 3 months of lamivudine with adefovir combination and adefovir dipivoxil (AD) alone in the treatment of patients with lamivudine-resistant hepatitis B virus (HBV) infection. Eligible patients were hepatitis B surface antigen-positive men and women with compensated liver disease who were given lamivudine at least more than 6 months and had HBV polymerase gene mutation. Patients were assigned to receive adefovir 10 mg/day (Group 1) or adefovir 10 mg once daily and lamivudine 100 mg once daily combination during first 3 months, and then stopped lamivudine and continued adefovir (Group 2).